DWA
KZR

Dorsey Wright & Associates’s Kezar Life Sciences KZR Stock Holding History

Dorsey Wright & Associates’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-360
Closed -$60K – 299
2022
Q1 		$60K Buy
+360
New +$51.7K 0.01% 157

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Dorsey Wright & Associates's KZR Position: Q2 2022 in Review

Dorsey Wright & Associates sold out of Kezar Life Sciences (KZR) in Q2 2022, closing a stake of 360 shares — an estimated $60K sold.

Dorsey Wright & Associates first reported a position in KZR in Q1 2022 and held it in 1 quarter. The position peaked at $60K in Q1 2022. 127 funds tracked by Wall St. Rank hold KZR as of Q2 2022.

  • Dorsey Wright & Associates reported no remaining Kezar Life Sciences position as of Q2 2022 after selling out during the quarter.
  • Dorsey Wright & Associates sold 360 Kezar Life Sciences shares in Q2 2022, an estimated $60K.
  • Dorsey Wright & Associates first reported a position in Kezar Life Sciences in Q1 2022 and held it in 1 quarter.
  • Dorsey Wright & Associates's Kezar Life Sciences position peaked at $60K in Q1 2022.
  • 127 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2022.

Based on Dorsey Wright & Associates's 13F filing for Q2 2022, filed 20 Jul 2022.